Report copyright - ABSORB JAPAN - European Society of Cardiology · ABSORB Japan Conclusions In the ABSORB Japan trial, BVS demonstrated a similar mid-term (12-month) clinical safety and efficacy profile
Please pass captcha verification before submit form